Hoth Therapeutics announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases. Hoth will form and operate a new wholly owned subsidiary named Merveille.ai, which will focus on screening for collaborative opportunities utilizing Artificial Intelligence in the field of drug discovery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOTH:
- Hoth Therapeutics granted Pre-IND meeting for HT-KIT by FDA
- Biotech Alert: Searches spiking for these stocks today
- Hoth Therapeutics prices 1.1M share direct offering at $2.63 per share
- Hoth Therapeutics announces ‘positive’ results for HT-KIT studies
- Hoth reports FDA accepts Pre-IND submission for HT-KIT